Capsids of the B19 parvovirus are composed of major (VP2; 58 kD) and minor (VP1; 83 kD) structural proteins. These proteins are identical except for a unique 226 amino acid region at the amino terminus of VP1. Previous immunization studies with recombinant empty capsids have demonstrated that the presence of VP1 was required to elicit virus-neutralizing antibody activity. However, to date, neutralizing epitopes have been identified only on VP2. Crystallographic studies of a related parvovirus (canine parvovirus) suggested the unique amino-terminal portion of VP1 assumed an internal position within the viral capsid. To determine the position of VP1 in both empty capsids and virions, we expressed a fusion protein containing the unique region of VP1. Antisera raised to this protein recognized recombinant empty capsids containing VP1 and VP2, but not those containing VP2 alone, in an enzymelinked immunosorbent assay. The antisera immunoprecipitated both recombinant empty capsids and human plasma-derived virions, and agglutinated the latter as shown by immune electron microscopy. The sera contained potent neutralizing activity for virus infectivity in vitro. These data indicate that a portion of the amino terminus of VP1 is located on the virion surface, and that this region contains intrinsic neutralizing determinants. The external location of the VP1-specific tail may provide a site for engineered heterologous epitope presentation in novel recombinant vaccines. (J. Clin. Invest. 1992.
Introduction
Parvoviruses are small, unenveloped, single-stranded DNA viruses widely distributed in the animal kingdom. The human B19 parvovirus causes several diseases in humans (1) . In the normal host, the virus is rapidly cleared by a brisk antibody response, and illness is usually mild and self limited. In other hosts characterized by a susceptible target cell population or an inadequate immune system, B 19 parvovirus causes significant morbidity and mortality. The target cell for B19 infection is an immature erythrocyte progenitor at about the CFU-E stage of development. The virus is directly toxic to this cell and completely ablates erythroid colony formation in bone marrow cultures (2) . In patients with increased requirements for erythrocytes or shortened red cell survival, acute B 19 infection causes the rapid development of severe anemia and the syndrome of transient aplastic crisis (TAG)1 (1) . TAC can be treated supportively with transfusions and resolves with the development of a specific antibody response. In immunocompromised hosts, the antibody response to parvovirus is inadequate, and persistent infection causes the gradual onset of a severe anemia. Persistently infected patients can be treated effectively with immunoglobulins, but in the face of unremitting or severe immunocompromise, such as occurs in infection with the human immunodeficiency virus, they often relapse (3) . The developing fetus is also susceptible to B 19 parvovirus, and severe anemia leads to spontaneous abortion or hydrops fetalis. Hydrops can be treated with intrauterine exchange transfusions, but it may not be recognized in time to avoid fetal death (4) . In all three of these groups, therapy is expensive and carries significant risks, making a preventive strategy attractive. Normal clearance of the virus appears to be achieved almost entirely through the humoral arm of the immune response, and effective vaccines have been developed for the related canine and feline parvoviruses (5) , suggesting that prevention of B19 parvovirus infection can be achieved through use of a vaccine.
The structural proteins ofB 19 are encoded by two overlapping reading frames on the right side of the viral genome. The major capsid protein (VP2) is translated from an RNA generated by a splicing event that removes the 5' 678 nucleotides of the minor capsid protein (VP 1) coding region. Thus, the amino acid sequences of the two proteins are identical except for 226 residues on the amino terminus ofVP1. 60 copies ofthe capsid proteins assemble into an icosahedral shell with -95% VP2 and 5% VPl. The structural distribution of VP1 and the position ofits unique tail are unknown. In many parvoviruses, this tail has a disproportionate number of basic amino acids and has been assumed to be located within the capsid, where it would partially neutralize the negative charge ofthe viral DNA (6, 7). 
Methods
Molecular cloning and gene expression of the unique amino-terminal region of VPJ. To express the VP1 protein-specific region ofB 19, DNA from the serum of a viremic patient was extracted with phenol in the presence of sodium dodecyl sulfate. A 68 l-bp DNA fragment encompassing nucleotides 2444 to 3124 ofthe B19 genome (12) was amplified by the polymerase chain reaction using primers 5'-GGAAGATCT-CATGAGTAAAGAAAGTGGCAAATGG-3' and 5'-CGCGGGATC-CAAGCTTGGGTATTTTTCTGAG-3'. Using the engineered BglII and BamHI restriction sites in the primers, amplified DNA was cloned into the transcription vector pSP72 (Promega Biotech, Madison, WI) and then completely sequenced. Homology with the previously reported sequence of this region ofthe parvovirusgenome (12) was 99.3% (676 of the 681 nucleotides were identical; two amino acids were changed). This VPI-specific sequence was subcloned into an Escherichia coli plasmid expression system (13) . The VPl-specific sequence was inserted (either as a single copy or as a tandem repeat) downstream of the tac promoter and sandwiched between sequences coding for the amino terminal 23 amino acids of the bacteriophage lambda cro protein and a segment encoding the last 17 residues of beta-galactosidase. The resultant plasmids, designated pCro VP1-227M (single copy) and pCro VP1-227D (tandem repeat) were used to transform E. coli strain NF1829 by standard procedures (14) . Induction of transformed cultures with isopropyl-beta-D-thiogalactoside (IPTG) resulted in production of the respective 33-kD and 64-kD fusion proteins. These fusion proteins, which are produced in bacteria as insoluble aggregates, were partially purified by previously described procedures (15) . Induced bacteria were harvested, treated with lysozyme (400 gg/ml, 4°C for 15 min), adjusted to 1% Triton X-100, and then sonicated. MgCI2 and DNase I were added to the resulting lysate to a final concentration of 5 mM and 10 Mg/ml, respectively. After incubation at 37°C for 30 min, the mixture was layered onto a 35% sucrose solution in an SW28 ultracentrifuge tube and centrifuged at 50,000 g for 60 min. Pelleted material was resuspended in STE (150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA) and repelleted by centrifugation at 10,000 g for 10 min.
The pellet was resuspended in STE to a protein concentration of 2-5 mg/ml and then adjusted to 1% SDS, 2% 2-mercaptoethanol. After boiling for 5 min, this solution was extensively dialyzed against STE (pH 8.5), 0.01% 2-mercaptoethanol, and 10% sucrose.
Rabbit antisera. Dialyzed fusion proteins (1 mg) were emulsified in complete Freund's adjuvant and administered intramuscularly to rabits. The animals were boosted with 0.5 mg of protein emulsified in Freund's incomplete adjuvant 3 wk after the initial immunization, and two additional booster immunizations were given at 5 and 7 wk. Animals were bled 2 wk after booster immunizations and samples were evaluated for antibodies by radioimmunoprecipitation.
Immunoblotting. Human serum containing B19 virions was boiled in Laemmli sample buffer, electrophoresed through an 8% SDS-polyacrylamide gel, and electrophoretically transferred to PVDF membranes (United States Biochemical Corp., Cleveland, OH) at 100 mA for 16 h. Transfer buffer contained 25 mM Tris and 192 mM glycine. Membranes were blocked with 1% blocking solution (United States Biochemical Corp.), incubated with antisera diluted 1:500, and incubated with alkaline phosphatase conjugated goat anti-rabbit immunoglobulin (Gibco BRL Life Technologies, Gaithersburg, MD). Antibody incubations were performed for 1 h at room temperature, and the membranes were washed three times with a salt buffer containing 0.1% Tween 20 between incubations. After soaking the membranes with substrate buffer (100 mM Tris, pH 9.5, 100 mM NaCl, 50 mM MgCl2), bound antibody was detected with a substrate solution containing nitroblue tetrazolium (NBT) (Gibco BRL Life Technologies) and BCIP (Gibco BRL Life Technologies).
Antigen-down ELISA. Spodoptera frugiperda Sf9 cells (American Type Culture Collection, Rockville, MD) were infected with recombinant baculoviruses bacVPI and bacVP2, combined in ratios of0:1, 1:1, and 10:1. Cells were cultured in Grace's insect medium (Gibco BRL Life Technologies) in room air, 95% humidity, at 27°C. Cells were harvested 3 d after inoculation and lysed by Dounce homogenization in a solution containing 5 mM 2-mercaptoethanol and 0.2% Triton X-100. Lysates were centrifuged at 100,000 gfor 16 h over 40% sucrose in HBSS. Pellets were resuspended in CsCl at an initial density of 1.31 g/ml and centrifuged at 100,000 g in an SW41 rotor for 40 h at 18°C. Visible bands containing empty capsids were collected and dialyzed into HBSS, and the presence of B19 structural proteins was verified by SDS-PAGE and immunoblot.
ELISA plates were prepared by attaching 1 ,g of purified empty capsids to each well of Immulon-2 96-well microtiter plates (Dynatech Laboratories Inc., Chantilly, VA) by overnight incubation in PBS at 4°C. 100 M1 of diluted rabbit antiserum was added to each well after blocking with PBS containing 3% bovine serum albumin. Plates were washed with PBS containing 0.05% Tween 20 and incubated with peroxidase-labeled goat anti-rabbit antibodies (Gibco BRL Life Technologies) for 1 h at room temperature. After a second wash, 200 Ml of0. For full virions, serum containing infectious virus was diluted 1:10 with PBS, and 10 Mul was precleared by incubation with beads alone, followed by preimmune rabbit serum. Immunoprecipitation was performed as described above. After the last wash, beads were resuspended in 1/3 N NaOH and boiled for 5 min. Samples were neutralized with an equal volume of 1/3 N HCI and blotted onto Nytran filters (Schleicher and Schuell Inc., Keene, NH) using a manifold (Slot Blot; Schleicher and Schuell). Filters were UV-cross-linked in an oven (StrataLink; Stratagene Inc., La Jolla, CA), prehybridized at 420C for at least 2 h, and hybridized at 420C for 12 h in 50% formamide, 5x standard saline citrate (SSC), lx Denhardt, 0.5% sodium dodecyl sulfate, 10% Dextran, and 100 jg/ml salmon sperm DNA. Virus-specific DNA probes were made by excising the viral sequence from pYT103c, a plasmid containing a nearly full-length B19 clone, and labeling with a random hexanucleotide labeling kit (Stratagene Inc.). After hybridization, filters were washed sequentially with 2x SSC, 2x SSC/I% SDS, 0.IX SSC/l% SDS, and 0. IX SSC. Prehybridization, hybridization, and washing were performed in a Hybridiser oven (Techne Inc., Princeton, NJ).
DNase treatment. I ,ul ofinfectious serum was diluted to 10 yd with PBS containing 6 mM MgCl2 and 0.1 mM CaCl2. 1 Al of RQ-I DNase (Promega Biotech) was added and the mixture was incubated for 30 min at 37°C. Loss of DNase activity caused by the addition of serum components was assessed by digesting template DNA that had been added to similarly diluted normal human serum.
Electron microscopy. Empty capsids containing VPI and VP2 were prepared as described above. After ultracentrifugation through 40% sucrose, the pellet was resuspended in HBSS and diluted 1:25 in distilled water. Capsids were negatively stained using 3% phosphotungstic acid, pH 6.5. Grids were examined to determine ifcapsids were intact.
Human serum containing infectious virions was diluted and stained as described above. Immune electron microscopy was performed to determine the antibody activity ofimmune and preimmune rabbit antisera using previously described techniques (8) .
Neutralization assays. Antibody-containing serum was heated to 56°C for 30 min to inactivate complement. Serum was then mixed with a 1:20 dilution ofhuman serum containing infectious B 19 parvovirus and incubated for 2 h at 4°C. Bone marrow was harvested from a normal volunteer under a protocol approved by the National Heart, Lung, and Blood Institute Institutional Review Board, and mononu- Figure 3 . Electron microscopy of sedimented empty capsids. Direct electron microscopy of empty capsids containing VPl and VP2 (A) or VP2 alone (B), expressed in a baculovirus expression system and centrifuged through 40% sucrose.
size of 83 kD and failed to detect the smaller but more abundant 58-kD VP2 protein (Fig. 1 ). An enzyme-linked immunosorbent assay was used to confirm the specificity of the anti-VP 1 sera against nondenatured capsids. Antisera failed to react with empty capsids containing only VP2, but reacted strongly with empty capsids containing two different concentrations of VPl (Fig. 2) . Reactivity was proportional to the VPl content of the capsids.
Immunoprecipitation ofempty capsids. Initial screening of the antisera by radioimmunoprecipitation suggested that the unique region of VP1 was on the external surface of recombinant empty capsids. We compared immunoprecipitation using the VP I specific sera with immunoprecipitation using antisera raised against intact empty capsids containing both VPl and VP2. Labeled capsids were produced in Sf9 cells infected with recombinant baculoviruses encoding the VP1 and VP2 sequences. To avoid detection of free proteins or incompletely assembled capsids, capsids were purified from cell lysates by centrifugation through a sucrose cushion. This technique routinely produces empty capsids with a uniform sedimentation coefficient of 70S upon rate-zonal centrifugation. Integrity of sedimented capsids was confirmed by electron microscopy, which showed that over 99% of capsids were intact (Fig. 3) .
Both antisera raised to the VP 1-specific region and antisera raised against empty capsids containing both structural proteins were able to precipitate capsids (Fig. 4 B) . Immunoprecipitation of virions. To determine if the position ofthe unique VP1 region was similar in recombinant capsids and DNA-containing virions, we performed a second set of immunoprecipitation experiments. Because B19 parvovirus can only be reliably propagated in fresh human bone marrow culture (16) , conventional immunoprecipitation techniques that follow metabolic labeling of the virion proteins are cumbersome, and high specific activity is not achieved. In addition, like other parvoviruses, B 19 produces both empty capsids and intact virions during the course of infection. These species appear to have similar but not identical antigenic properties, and they would be impossible to distinguish by detection of metabolically labeled proteins. To circumvent these problems, human serum known to contain a high level of infectious virus was immunoprecipitated and captured virus was measured by DNA slot blotting and hybridization with a B 19-specific DNA probe (Fig. 4 A) . In this assay, both anti-VP1 antiserum and antiserum raised against empty capsids containing both VPl and VP2 were able to precipitate virus. It has been hypothesized for other parvoviruses that VPl may play a role in neutralizing the charge of virion DNA. To control for the possibility that we were detecting incomplete or fragmented virions (where VPl might be associated with virion DNA but not assembled into complete capsids) the virus-containing serum was treated with DNase before immunoprecipitation (DNA in infectious virions is known to be DNase resistant [2] ). DNasetreated serum showed no loss of DNA signal when compared with untreated serum (data not shown).
Specific reactivity of anti-VP1 antisera and intact virions was confirmed by immune electron microscopy. Rabbit antisera agglutinated serum-derived B 19 virions and coated them with antibody, while preimmune serum neither agglutinated nor coated similarly prepared virus (Fig. 5) .
Neutralization. All four rabbit antisera produced after immunization with the VP1-specific fusion peptide or its dimer showed virus neutralizing activity in vitro. To assess the relative neutralization titers of these antisera, increasing dilutions were assayed for neutralization ability (Fig. 6 ). All sera maintained their ability to neutralize virus to at least a 1/10 dilution, and three ofthe four antisera had measurable neutralizing activ- VPl and VP2. The structural unit ofthese proteins is an identical eight-stranded anti-parallel beta barrel homologous to similar structures in many other icosahedral viruses (6) . VPl and n VP2 differ in the presence on the former ofa unique amino-ter-1:100 minal domain. The structure ofcanine parvovirus has recently been solved to the atomic level by x-ray crystallography, and the position of VP2 in this virus is now known exactly (6) . Canine parvovirus has a capsid protein distribution similar to B19, with the majority of the capsid made up of VP2 (or its derivative, VP3). The VPI tail and the amino terminal 37 amino acids of VP2 are not detected by crystallographic techniques, probably because their position on the virion is not symmetric and is insufficiently constrained. Residue 38 ofVP2 lies within the capsid, beneath a hollow cylinder on the fivefold axis, raising the possibility that the end ofVP2 and perhaps the VPl tail may extend through this cylinder to the outside ofthe virus. In support ofthis hypothesis, an ill-defined electron density was reported within the cylinder in virions that was absent in empty capsids, suggesting that the incorporation of DNA was associated with entry ofthe ends ofthe capsid proteins into the cylinders (6) . Symmetry considerations (7) and the assumption that the basic residues on VPl help stabilize the viral DNA led to the prediction that VPl folds inside the viral capsid, and only the amino terminus of VP2 would enter the cylinders. We (17) , and later others (18) , have demonstrated that specific reactivity to the VPl unique region develops during natural infection and that VP1 is the dominant species recognized by convalescent human serum (17 parvoviruses have been mapped to regions ofVP2 (20) , making this a more likely area for receptor binding in these structurally similar viruses. Either as a membrane contact region or receptor ligand, VP I would be expected to be an efficient target for neutralizing antibody. Reciprocal Serum Dilution External localization of the VPl tail only partially explains the requirement for VP1 to be present to generate neutralizing antisera. While VPl clearly does contain neutralizing epitopes, we and others have identified other neutralizing epitopes on VP2 (9-11). Neutralizing monoclonal antibodies directed against these VP2 epitopes recognize empty capsids containing only VP2, but have only been generated using intact virions as immunogens. This observation suggests that, in addition to containing neutralizing epitopes, VPl modulates the antigenicity of epitopes present on VP2, perhaps by exposing otherwise cryptic antigens on the viral capsid or influencing the processing and presentation of capsid proteins by cells of the immune system.
Humoral recognition of VP1-specific epitopes appears to be important for restricting B19 infection in vivo. The early antibody response in humans infected with the virus is directed almost entirely against VP2. As the response matures, however, the primary protein detected on immunoblots becomes VP 1, despite the much lower relative concentration of the minor capsid protein ( 17) . In persistently infected patients, including HIV-infected individuals who are able to generate high levels of B19-specific antibody, this switch from VP2 to VPl reactivity does not occur. VPl is also the major specificity of pooled human immunoglobulin (17) , used in the treatment of chronic infection. Thus, responsiveness to VPl correlates with in vivo activity against the virus.
The external location ofthe VP1 tail in empty capsids provides a unique site for engineering recombinant vaccines and protein delivery systems. While some portion of the VPl protein must pass through the protein shell, our data suggest that the majority is external, unconstrained, and antigenic. The loops can be replaced with foreign oligopeptides (21) (22) (23) , the external domain of VP1 may be able to accommodate large heterologous protein domains, allowing the presentation of multiple antigenic sites or the delivery of enzymatic activity. If self-assembly can occur with heterologous proteins replacing the tail ofVP 1, a baculovirus production system would provide a ready source of easily purified and safe antigen for vaccine development.
